Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teriflunomide in well-controlled coeliac disease during short gluten challenge (phase IIa)
2020-002307-18Phase 2Completed
- Sponsor
- Oslo University Hospital
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in celiac disease comparing Teriflunomide 14 mg with Placebo (2 arms). Primary endpoint: CD38 activation on gluten-reactive T cells. Started Jul 2020; status: completed.
02
Drugs
teriflunomide
03
Conditions
celiac disease
Beyond the preview
Go deeper on 2020-002307-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002307-18.